260267-07-0

Basic information

• Product Name: 5,6-Difluoro-1H-indole-3-carboxaldehyde
• Synonyms: 5,6-Difluoro-1H-indole-3-carboxaldehyde;5,6-Difluoro-1Hindole-3-carbaldehyde;5,6-difluoroindole-3-carboxaldehyde;5,6-difluoroindole-3-carbaldehyde
• CAS NO: 260267-07-0
• Molecular Formula: C₉H₅F₂NO
• Molecular Weight: 181.14
• Mol File: 260267-07-0.mol

Chemical Properties

• Boiling Point: 348.2 °C at 760 mmHg
• Flash Point: 164.4 °C
• Appearance: /
• Density: 1.485
• PKA: 14.06±0.30(Predicted)
• CAS DataBase Reference: 5,6-Difluoro-1H-indole-3-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-Difluoro-1H-indole-3-carboxaldehyde(260267-07-0)
• EPA Substance Registry System: 5,6-Difluoro-1H-indole-3-carboxaldehyde(260267-07-0)

Safety Data

• Hazardous Substances Data: 260267-07-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5,6-Difluoro-1H-indole-3-carboxaldehyde is used as an intermediate in the synthesis of various biologically active compounds for the development of new drugs with potential therapeutic uses. Its unique chemical structure and properties make it a valuable component in the creation of innovative pharmaceutical formulations.
Used in Agrochemical Industry:
5,6-Difluoro-1H-indole-3-carboxaldehyde is also used as an intermediate in the synthesis of agrochemicals, contributing to the development of new pesticides, herbicides, and other agricultural chemicals. Its unique properties allow for the creation of more effective and targeted agrochemical products.
It is important to handle 5,6-Difluoro-1H-indole-3-carboxaldehyde with caution and adhere to all safety protocols when working with it in a laboratory setting to ensure the safety of researchers and the integrity of the experiments.

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 169674-01-5 5,6-difluoro-1H-indole 
• 2927-34-6 3,4-difluorotoluene 
• 468718-05-0 3,4-difluoro-5-nitrotoluene 

Downstream Products

• 468718-07-2 5,6-difluoro-1-(toluene-4-sulfonyl)-1H-indole-3-carbaldehyde 

Relevant articles and documents

INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)

The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Spirotetrahydro β-carbolines (spiroindolones): A new class of potent and orally efficacious compounds for the treatment of malaria

The antiplasmodial activity of a series of spirotetrahydro β-carbolines is described. Racemic spiroazepineindole (1) was identified from a phenotypic screen on wild type Plasmodium falciparum with an in vitro IC50 of 90 nM. Structure-activity relationships for the optimization of 1 to compound 20a (IC50 = 0.2 nM) including the identification of the active 1R,3S enantiomer and elimination of metabolic liabilities is presented. Improvement of the pharmacokinetic profile of the series translated to exceptional oral efficacy in the P. berghei infected malaria mouse model where full cure was achieved in four of five mice with three daily doses of 30 mg/kg.

(AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES

The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, nitro, alkyl, alkoxy and the like; X1, X2 and X3 independently represent CR2 or N; R1 and R2 independently represent halogen, cyano, haloalkyl, A-D-E-G, -N(-D-E-G)2 and the like, in the formula, A represents a single bond, O, S and the like; D and G independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E represents a single bond, O, S, COO, SO2 and the like.

1,2-Diarylacetylene Derivatives of Acyltryptophanols

The present invention relates to acyltryptophanols of the general formula I, in which Q, W, R1, R2, R3, R4, R5, R6, R7 and R8 have the meaning as defined in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.

3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I) wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.

Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists

A chemical compound of formula (I), wherein n is 1, 2 or 3; R1and R2are independently selected from hydrogen and alkyl; R3is alkyl; R4to R7are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, or R5and R6together form a carbocyclic or heterocyclic ring, and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders, diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity